One More Plea for Avastin in Breast Cancer

posted on Aug 08 by MedPage Today OB/Gyn in the Uncategorized category WASHINGTON (MedPage Today) -- As Genentech awaits word from the FDA on whether bevacizumab (Avastin) will lose its breast cancer indication, the company is urging the agency to consider a "middle ground" approach that would continue the drug's approval in metastatic disease.